Regulatory timeline
Federal safety actions on COVID-19 vaccines, in order: signals, pauses, recommendations, warnings, label changes, restrictions and withdrawals — with whether each is still current, was superseded, or was a signal later evaluation did not confirm. A preliminary signal is never shown as an established finding.
Topic: All · Myocarditis and pericarditis · Blood clots and thrombosis with thrombocytopenia (TTS) · Stroke · Guillain-Barré syndrome
Agency: FDA · CDC
-
FDA adds a myocarditis and pericarditis warning to Pfizer and Moderna fact sheets
Product: Pfizer-BioNTech and Moderna COVID-19 vaccines · Population: Recipients, particularly after dose 2 and in young males
What changed: Provider fact sheets gained a myocarditis/pericarditis warning; recipient fact sheets gained information on symptoms.
FDA revised both mRNA vaccines' fact sheets after ACIP reviewed reports suggesting increased risks of myocarditis and pericarditis, particularly after the second dose and with onset within a few days.
Later labeling (2025) added incidence estimates.
Later: Labeling updated with incidence estimates on June 25, 2025.
-
Novavax vaccine authorized with a myocarditis and pericarditis warning
Product: Novavax COVID-19 Vaccine, Adjuvanted · Population: Recipients
What changed: Authorized with a warning that clinical-trial data provide evidence for increased risks of myocarditis and pericarditis.
The Novavax fact sheet warns that clinical-trial data provide evidence for increased risks of myocarditis and pericarditis; six cases were detected among 41,546 trial recipients aged 16 and older.
Trial case counts are small; the wording is the regulator's.
-
FDA requires updated myocarditis and pericarditis warning for mRNA COVID-19 vaccines
Product: Comirnaty (Pfizer-BioNTech); Spikevax (Moderna) · Population: Recipients of mRNA COVID-19 vaccines; highest estimated incidence in males 12–24
What changed: Warnings in Comirnaty and Spikevax labeling updated with incidence estimates and cardiac MRI follow-up results; EUA fact sheets for children 6 months–11 years updated.
FDA approved required labeling changes adding an estimated unadjusted incidence of myocarditis and/or pericarditis after the 2023–2024 formula of mRNA COVID-19 vaccines — about 8 cases per million doses in people 6 months through 64 years old, and about 27 cases per million doses in males 12 through 24 — and results of a cardiac MRI study in which abnormal findings often persisted at about five months.
FDA states that the clinical and prognostic significance of the persistent MRI findings is not known and that longer-term studies are under way.
Thread: myocarditis
- Warning — FDA adds a myocarditis and pericarditis warning to Pfizer and Moderna fact sheets Superseded
- Authorization — Novavax vaccine authorized with a myocarditis and pericarditis warning Current
- Label change — FDA requires updated myocarditis and pericarditis warning for mRNA COVID-19 vaccines Current